Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by LSV Asset Management

LSV Asset Management trimmed its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 84.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 158,429 shares of the biotechnology company's stock after selling 879,211 shares during the quarter. LSV Asset Management owned approximately 0.05% of Exelixis worth $3,801,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Fisher Asset Management LLC raised its holdings in Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 728 shares during the period. Contravisory Investment Management Inc. purchased a new stake in shares of Exelixis in the fourth quarter worth $26,000. GAMMA Investing LLC purchased a new position in shares of Exelixis during the 4th quarter valued at $27,000. Fifth Third Bancorp increased its stake in Exelixis by 44.2% in the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company's stock worth $43,000 after buying an additional 604 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in Exelixis during the third quarter valued at about $100,000. 85.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on EXEL. Barclays downgraded Exelixis from an "overweight" rating to an "equal weight" rating and set a $25.00 target price on the stock. in a research note on Thursday, April 11th. William Blair reissued an "outperform" rating on shares of Exelixis in a report on Wednesday, May 1st. Stifel Nicolaus boosted their target price on Exelixis from $23.00 to $25.00 and gave the stock a "hold" rating in a research report on Friday, February 2nd. TD Cowen lifted their price objective on Exelixis from $25.00 to $27.00 and gave the stock a "buy" rating in a research note on Wednesday, May 1st. Finally, TheStreet raised shares of Exelixis from a "c+" rating to a "b-" rating in a report on Monday, March 18th. Six research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $26.33.

Exelixis Trading Up 0.8 %

Shares of NASDAQ EXEL traded up $0.17 during trading hours on Thursday, reaching $21.76. The stock had a trading volume of 1,420,956 shares, compared to its average volume of 2,312,119. The business's fifty day moving average price is $22.98 and its two-hundred day moving average price is $22.24. The firm has a market cap of $6.34 billion, a price-to-earnings ratio of 33.73, a P/E/G ratio of 0.59 and a beta of 0.57. Exelixis, Inc. has a 52-week low of $18.52 and a 52-week high of $24.34.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The business had revenue of $425.23 million for the quarter, compared to the consensus estimate of $461.04 million. During the same quarter in the previous year, the company earned $0.12 earnings per share. The firm's revenue was up 4.0% on a year-over-year basis. Equities research analysts anticipate that Exelixis, Inc. will post 1.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Exelixis news, Director Alan M. Garber sold 19,205 shares of Exelixis stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $24.01, for a total value of $461,112.05. Following the transaction, the director now owns 35,703 shares in the company, valued at $857,229.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Exelixis news, Director Alan M. Garber sold 19,205 shares of the firm's stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $24.01, for a total value of $461,112.05. Following the completion of the sale, the director now directly owns 35,703 shares in the company, valued at $857,229.03. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Patrick J. Haley sold 47,020 shares of the stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the sale, the executive vice president now owns 384,866 shares of the company's stock, valued at approximately $8,255,375.70. The disclosure for this sale can be found here. 2.85% of the stock is owned by company insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.